Stocks to Watch Today: Swiggy, Wipro, Lupin, Coal India, Tata Elxsi in Focus

Swiggy Fails to Secure Shareholder Approval

Food delivery and quick commerce company Swiggy will remain in focus after shareholders rejected a special resolution related to amendments in the company’s Articles of Association. The proposal received 72.36 percent approval, lower than the mandatory 75 percent threshold required for special resolutions. The amendments were part of Swiggy’s broader strategy to qualify as an Indian Owned and Controlled Company (IOCC) under Indian foreign exchange regulations. The development may delay the company’s restructuring plans and could impact future strategic initiatives linked to ownership norms.

Tata Elxsi Launches AI Platform for Healthcare

Tata Elxsi announced the launch of AnaTel, an AI-native software development platform designed for healthcare and medical technology companies. The platform has been developed in collaboration with OpenAna and is aimed at accelerating AI-driven software engineering in the healthcare sector. The launch highlights Tata Elxsi’s growing focus on artificial intelligence and digital healthcare solutions, segments expected to witness strong growth in the coming years.

RITES and Crisil Sign Strategic MoU

Engineering consultancy firm RITES signed a Memorandum of Understanding with Crisil to develop integrated and data-driven infrastructure solutions. The partnership combines RITES’ expertise in transport infrastructure and engineering consultancy with Crisil’s strengths in analytics, research, and market intelligence. The collaboration is expected to support better project execution and planning in infrastructure development projects.

Pharma Stocks in Focus on Regulatory Developments

Several pharmaceutical companies are likely to attract investor attention following major regulatory updates.

Lupin received the Establishment Inspection Report (EIR) from the US Food and Drug Administration for its Ankleshwar facility in Gujarat. The report was issued after the successful closure of a pre-approval inspection conducted earlier this year, strengthening the company’s compliance profile in international markets.

Indoco Remedies also received positive news after securing EU GMP certification from the German Health Authority for its oral solid dosage manufacturing facility located in Baddi, Himachal Pradesh. The certification may support the company’s expansion in European markets.

Wockhardt received approval from the Central Drugs Standard Control Organisation for the import and marketing of its antibiotic Zaynich in India. The drug is approved for treating complicated urinary tract infections and Gram-negative bacterial infections.

Meanwhile, Zydus Lifesciences gained attention after the US FDA granted Priority Review for the New Drug Application of saroglitazar. The drug is intended for the treatment of primary biliary cholangitis, and the regulator has set a target action date of November 27, 2026.

Wipro Expands AI Partnership

IT major Wipro announced an expanded partnership with ServiceNow to scale agentic AI workflows across enterprise functions including IT, HR, procurement, and cybersecurity. The collaboration reflects rising enterprise demand for automation and AI-powered business operations, which could strengthen Wipro’s digital transformation business globally.

Escorts Kubota and Coal India Also in Spotlight

Escorts Kubota launched the Kubota Neostar compact tractor series targeting high-potential agricultural segments such as sugarcane, horticulture, and vineyards across several states including Maharashtra and Karnataka.

Coal India will remain in focus after the government decided to exercise the oversubscription option in its offer-for-sale issue, increasing the total stake sale size from 1 percent to 2 percent. Patanjali Foods may also see market reaction after receiving a GST show cause notice worth ₹1,352.9 crore along with penalties and interest over alleged turnover discrepancies for FY23.